Compound learning guide · GHK-Cu
GHK-Cu attracts interest for skin, collagen and hair research. The useful question is what the copper peptide actually is—and how closely the studies match the benefit being claimed.
GHK-Cu is the copper complex of a three-amino-acid peptide: glycine–histidine–lysine. Scientists have studied it in cells, animal models and a limited number of human topical formulations. Some human studies reported improvements; one small post-laser trial found no objective advantage for its copper-peptide regimen.
A result from a particular serum, wound gel or combined cream does not establish the same result for another formula, an isolated laboratory reagent or a different route of exposure. This guide separates those materials and explains the studies behind common skin and hair claims.
What is GHK-Cu?
GHK names the short peptide glycyl-L-histidyl-L-lysine. “Cu” identifies copper coordinated to it, commonly described in the research literature as copper(II). GHK was originally isolated from human plasma; a synthetic laboratory material still needs its own chemical characterization. A naturally occurring sequence does not establish that an externally supplied material is safe or effective in people. Pickart et al., 1973; Maquart et al., 1988.
Material identity worksheet
Three residues. Copper changes the material being studied.
The peptide alone is GHK.
GHK coordinated with copper(II) → GHK-Cu.
The copper basis, chemical species and surrounding solution still need to be specified.
GHK-Cu is also discussed as copper tripeptide-1 in cosmetic research. That ingredient name does not tell you the full formula, delivery system, concentration or evidence for a finished product. It is also unrelated to the abbreviation hGH for human growth hormone.
GHK versus GHK-Cu: what difference does copper make?
They are related, but they are not interchangeable names. A useful comparison asks which material was present in the experiment, whether copper was added separately, and whether the outcome was reproduced with a copper-only control.
GHK
The peptide without a specified coordinated copper ion. Copper-free GHK has its own cell and reconstructed-skin literature; an effect of GHK should be identified as such.
GHK-Cu
A copper-coordinated GHK complex. The peptide and metal belong in the identity description; a peptide peak by itself does not establish every aspect of the metal complex.
AHK-Cu
A related copper peptide whose first amino acid is alanine rather than glycine. An often-cited 2007 hair-follicle paper tested this analog, not GHK-Cu.
A finished formulation
A serum, gel, cream or engineered carrier containing one of these materials. Its vehicle, other ingredients and delivery system can affect the result.
For example, a fibroblast study found increased MMP-2 expression with GHK-Cu and with copper ions, but not with GHK alone. Separate reconstructed-skin studies found some similar cellular changes with GHK and copper-GHK. Those results answer different experimental questions; they do not create a universal “stronger peptide” ranking. Siméon et al., 2000; Kang et al., 2009; Choi et al., 2012.
Technical identity: why published molecular weights can differ
Reference records distinguish GHK (PubChem CID 73587; C₁₄H₂₄N₆O₄; approximately 340.38 g/mol) from a particular positively charged GHK-copper species (CID 71587328; C₁₄H₂₃CuN₆O₄⁺; approximately 402.92 g/mol). Charge, protonation, counterions and hydration matter when comparing a registry entry with a physical material.
These are reference-species descriptions, not a universal formula for every commercial lot. Record the actual chemical basis before using a molecular weight for a laboratory calculation. GHK reference record; GHK-copper reference record.
What do human studies of GHK-Cu actually show?
Human studies exist. The important differences are the tested formula, comparison group, measured outcome and size of the study. The following are selected original reports, including positive findings and a study whose objective outcomes did not favor the copper-peptide regimen.
1994
Diabetic ulcer study
Controlled, multicenter topical-gel study
A wound gel within structured wound care
Reported finding: The study described greater closure of plantar ulcers with the tested GHK-copper gel than with vehicle. Both groups received standardized wound care, including pressure relief and debridement.
This was a clinical formulation used within a defined care program. It does not establish that a research reagent treats ulcers, that wound care is unnecessary, or that every subsequent formulation has the same outcome. Mulder et al., 1994.
2006
After laser resurfacing
Randomized regimens
13 completers
Objective results and satisfaction diverged
Reported finding: Blinded assessment and computer analysis found no significant advantage for the GHK-Cu regimen in redness resolution, wrinkle improvement or overall skin quality. One patient-questionnaire result favored that regimen.
A subjective improvement is worth recording, but it should not be rewritten as an objective superiority finding. The sample was also very small. Miller et al., 2006.
2016
Facial wrinkles
40 women enrolled
8 weeks
A positive result for a serum and its carrier
Reported finding: A blinded split-face study reported improved wrinkle measures with a GHK-Cu serum in a lipid-based carrier. Participants were allocated to two comparison groups; the active serum was consistently used on the right side.
The negative-control serum lacked both GHK-Cu and the carrier. The comparison therefore does not isolate the peptide from its delivery system. One participant stopped after a skin reaction affecting both compared sides. This is evidence for the studied formulation, not a promise for every copper-peptide product. Badenhorst et al., 2016.
2026
Combined face cream
32 enrolled; 30 completed
8 weeks
A combination study cannot isolate GHK-Cu
Reported finding: A cream combining GHK-Cu with a mixed-culture ferment extract was associated with improvements in selected wrinkle and barrier measurements compared with baseline.
The clinical study did not report a randomized comparison arm separating the ingredients. Laboratory tests compared components, but that does not supply the missing human comparison. The participants’ results belong to the combined cream. Wang et al., 2026; full methods.
These reports make a stronger case for studying particular topical formulations than for broad claims of whole-body rejuvenation. They do not establish a human benefit from Apex’s laboratory material. Study size, follow-up, outcome selection and independent replication remain important when judging how far a positive finding can travel.
A new trial registration is not a result. On September 8, 2026, NCT07437586 (CuHeal) listed a recruiting, planned 60-participant comparison of a GHK-Cu gel and vehicle in standardized acute wounds. No results were posted. Registry status is supplied by the responsible party and does not independently confirm recruitment or effectiveness.
Does GHK-Cu grow hair?
The evidence needs two distinctions: which copper peptide was tested, and whether the experiment involved isolated follicles or living participants.
2007 · AHK-Cu
Isolated human follicles
Pyo and colleagues tested AHK-Cu in human hair follicles outside the body and in cultured dermal-papilla cells. They reported follicle elongation and cell proliferation; the reduction in apoptotic cells was not statistically significant. The first amino acid differs from GHK-Cu. Original study.
2026 · GHK-Cu serum
A small eyebrow study
A proceedings article reported a blinded, vehicle-controlled split-face study in 18 participants over 12 weeks. The treated eyebrow showed improved hair-count and diameter measures. This is a small, formulation-specific report about eyebrows; it does not establish reversal of scalp pattern hair loss or outcomes from a research vial. Bo et al., 2026.
“Human hair follicles” is not another way to say “a human clinical trial.” Equally, the existence of a small clinical report should be acknowledged without turning it into a broad hair-regrowth guarantee.
Why is GHK-Cu studied for collagen and skin repair?
Much of the interest comes from extracellular-matrix research. The matrix is the supporting network around cells; collagen is one part of it. Repair requires both building and remodeling that network, so an increase in one laboratory marker does not by itself describe healthier skin.
Collagen production in cultured fibroblasts
Maquart and colleagues reported increased collagen synthesis in fibroblast cultures exposed to GHK-Cu. The finding was not explained by an increase in cell number. A later human-fibroblast study found a concentration-dependent pattern in certain glycosaminoglycans, with stimulation returning toward control levels at higher concentrations. These are cell-model findings, not a reason to assume that more material produces more benefit. 1988 collagen study; 1992 matrix study.
Matrix construction and remodeling in rat wounds
Experimental wound chambers in rats showed changes in collagen and other matrix components. Related studies measured matrix metalloproteinases—enzymes involved in remodeling—and their timing during repair. This is more specific than “GHK-Cu rebuilds tissue”: the reported responses depended on the wound model, measured component and stage of healing. Maquart et al., 1993; Siméon et al., 1999; Siméon et al., 2000.
Skin-cell markers are not a measurement of age reversal
Copper-GHK research in keratinocytes and reconstructed skin measured proliferation-related markers, including integrins and p63. These results help frame cellular hypotheses. They do not demonstrate that a person becomes biologically younger or that a product restores stem cells throughout the body. Kang et al., 2009.
Oxidative-stress and inflammation models have narrow scope
A biochemical experiment found inhibition of ferritin-dependent iron release and lipid peroxidation, without significant superoxide-dismutase-like activity. Mouse lung-injury and fibrosis studies measured inflammatory, oxidative and signaling changes in their respective models. These are different systems; they do not establish a general antioxidant treatment or a human lung indication. Miller et al., 1990; Park et al., 2016; Ma et al., 2020.
A peptide, a copper complex and a delivery system answer different questions
A formulation can change what reaches cells and how long it remains available. In a preformulation study, GHK-Cu was highly hydrophilic, and its stability depended on chemical conditions and formulation ingredients. That work helps explain why the vehicle matters; it does not supply a universal storage rule or a clinical dose. Badenhorst et al., preformulation study.
An engineered 2023 material combined a lipidated GHK derivative, copper and a hyaluronic-acid hydrogel. Its reported wound-model performance belongs to that complete material. It should not be presented as the result of isolated, unmodified GHK-Cu. Lee et al., 2023.
The same distinction applies to peptide blends. The GHK-Cu literature can motivate a question about a blend; it cannot establish that every component remains stable together or that the mixture has an additive benefit. The dedicated GLOW and KLOW guides explain their specific component and mixture boundaries.
What can be said about safety and benefit claims?
Safety depends on the actual material, formulation, exposure, population and observation period. Small topical studies cannot establish long-term safety, rare-event risk or the safety of a different route. A natural peptide sequence, a blue color or a high chromatographic area percentage cannot answer those questions.
The FDA’s current compounding safety-risk page specifically identifies concerns for GHK-Cu for injectable routes, including possible immunogenicity associated with aggregation and peptide-related impurities, with limited human safety information. That route-specific discussion is not a statement that every cosmetic product is approved, or that every use has the same regulatory status. FDA safety-risk record, checked September 8, 2026.
This guide explains research rather than recommending a skin routine, injection protocol or treatment. Apex’s GHK-Cu is a laboratory reagent, not the finished formulations described in the human studies.
How the research developed
The early literature moved from identification of a plasma tripeptide to studies of collagen, matrix remodeling and copper-dependent responses. Later work examined reconstructed skin, animal injury models and engineered carriers. Human formulation studies are a separate branch of that history, with their own comparisons and limitations.
Reviews can help locate these branches, but a review’s broad conclusion is not a new experiment. The 2008 tissue-remodeling review and 2026 aesthetic-medicine review provide context. The original studies above are the basis for this guide’s concrete outcome descriptions.
What makes a GHK-Cu study interpretable?
A good record lets another researcher understand the material before interpreting its result. That usually means specifying the peptide sequence, copper basis, counterion or reference species, lot, solution or matrix, and the relevant analytical methods.
Controls should follow the question. To distinguish a peptide effect from a metal effect, a study may need GHK-only, copper-only and GHK-Cu comparisons. To study a delivery system, the relevant comparison may include the same carrier without the active material. Vehicle, viability and model-appropriate positive controls help separate the intended effect from unrelated changes.
Those controls are useful because they address a practical ambiguity: did the measured change come from the peptide, the metal, the carrier, another ingredient or the model itself?
How to read a GHK-Cu research-material record
Apex lists GHK-Cu as a lyophilized research reagent. The following are two identified, published in-house COA examples. They are not independent third-party tests and do not identify a current shipping lot without a label match.
50 mg configuration
- Published lot
- APX-2026-0624-G
- Integrated detector area
- 99.915%
- Reported active content
- 50.0885 mg/vial
100 mg configuration
- Published lot
- APX-2026-0625-G
- Integrated detector area
- 99.92%
- Reported active content
- 100.01 mg/vial
The area percentage describes the assigned peak’s share of integrated detector signal under the stated method. Active content is a different measurement. Neither number alone establishes copper stoichiometry, sterility, endotoxin status or a biological outcome. Read the relevant tests and their units rather than collapsing the report into one “purity” score.
For the method background, see how to read a peptide COA and what HPLC purity does and does not measure.
Need the current research-material listing? Product configurations, availability and associated documentation belong on the live catalog page.
For a direct comparison with a different peptide, continue to BPC-157 versus GHK-Cu.
Frequently Asked Questions about GHK-Cu
What is GHK-Cu?
GHK-Cu is the copper-coordinated complex of the three-amino-acid peptide glycine–histidine–lysine. It is studied in laboratory models and in some topical formulations. A material’s identity does not establish a particular human benefit.
Are GHK and GHK-Cu the same?
No. GHK names the peptide; GHK-Cu identifies a copper-coordinated complex. Copper-free GHK, copper ions and a prepared GHK-Cu complex can answer different experimental questions, so the tested material should always be named.
What does GHK-Cu do for skin?
Laboratory studies have measured collagen, matrix-remodeling and skin-cell responses. Some small human formulation studies reported improvements, while a post-laser study found no objective advantage for its copper-peptide regimen. These results do not establish the same effect for every formula or an isolated research reagent.
Does GHK-Cu grow hair?
A small 2026 proceedings study reported improved eyebrow measures with a GHK-Cu serum. A frequently cited 2007 isolated-follicle experiment instead tested AHK-Cu, a different copper peptide. Neither establishes reversal of scalp pattern hair loss or outcomes from a research vial.
Is GHK-Cu a growth hormone?
No. GHK-Cu names a copper complex of a three-amino-acid peptide. It is not human growth hormone, and references to cell growth or growth-related markers do not make the two materials equivalent.
Does blue color prove GHK-Cu purity?
No. Color alone does not establish peptide sequence, copper composition, chromatographic purity, active content, sterility, endotoxin status or biological activity. Each question requires the relevant evidence for the identified material.
Do positive skin studies establish injectable GHK-Cu safety?
No. The tested formulation and route matter. Small topical studies do not establish safety for another route, long-term exposure or rare adverse events. The FDA separately identifies injectable-route GHK-Cu safety concerns and limited human safety information.
Can GHK-Cu findings be assigned to GLOW or KLOW?
Not automatically. A component study can support a research question about a mixture, but it does not establish the mixture’s stability, compatibility or combined biological effect. The exact components and tested formulation must match the claim.
References and source notes
Primary study records are linked beside their claims. The source check includes PubMed records, original publisher reports and the named clinical-trial registry record checked September 8, 2026. This is a selected evidence review, not a claim to include every unpublished study or every commercial formulation.
- Pickart L et al. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973. PMID 4349963.
- Maquart FX et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID 3169264.
- Miller DM et al. Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Adv Exp Med Biol. 1990. PMID 2244543.
- Wegrowski Y et al. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992. PMID 1522753.
- Maquart FX et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993. PMID 8227353.
- Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994. PMID 17147644.
- Siméon A et al. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol. 1999. PMID 10383745.
- Siméon A et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000. PMID 11045606.
- Siméon A et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000. PMID 11121126.
- Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171.
- Pyo HK et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. PMID 17703734.
- Pickart L et al. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. PMID 18644225.
- Kang YA et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 2009. PMID 19319546.
- Choi HR et al. Stem cell recovering effect of copper-free GHK in skin. J Pept Sci. 2012. PMID 23019153.
- Badenhorst T et al. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol. 2016. PMID 25384620.
- Park JR et al. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016. PMID 27517151.
- Ma WH et al. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci. 2020. PMID 31809714.
- Lee S et al. In situ photo-crosslinkable hyaluronic acid-based hydrogel embedded with GHK peptide nanofibers for bioactive wound healing. Acta Biomater. 2023. PMID 37832839.
- Wang J et al. Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu. Skin Res Technol. 2026. PMID 42573538.
- Mokhtar J et al. The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthet Surg J. 2026. PMID 42619529.
- Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. Journal of Aging Science. 2016;4:166. Original publisher report. DOI: 10.4172/2329-8847.1000166.
- Bo SL et al. The efficacy of 2% copper peptide (GHK-Cu) serum for eyebrow hypotrichosis: a randomized, double-blind, vehicle-controlled, split-face comparative study. Procedia of Multidisciplinary Research. 2026;4(5). Original proceedings report.
Research use only. Apex Laboratory materials are chemical reagents for in-vitro and preclinical laboratory research. They are not intended for human or veterinary use. This educational guide does not provide dosing or administration advice.
About the author: Nicholas Tremelling writes research explainers for Apex Laboratory. Reviewed by the Apex Laboratory Editorial Team. Sources checked September 8, 2026. See the editorial standards for sourcing and corrections.
